ClinicalTrials.gg
RecruitingNCT06530251Updated Mar 4, 2026

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

A Phase 1/2 interventional study of AK112 and Cadonilimab in Hepatocellular Carcinoma, sponsored by Akeso. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Akeso · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Carcinoma, Hepatocellular by Akeso — 5 open to participants now, 6 under way, 2 of them phase 3. Carcinoma, Hepatocellular · Akeso.

Planned enrollment
3rd of 10
280 · median 80
Started
2024
with 1 other
Phase 1/2
2 of 10
1 open now
Registered
8th of 10
by date

Among the 10 studies in Carcinoma, Hepatocellular by Akeso, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2024, is one of 2 in phase 1/2, and was the 8th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

5 of the 10 studies in Carcinoma, Hepatocellular by Akeso are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Carcinoma, Hepatocellular by Akeso, or all of them as a file.
02

Study summary

There're 2 parts in this interventional study:

  1. The goal of phase Ib trial is to evaluate the safety and tolerability of AK112 in combination therapies for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced hepatocellular carcinoma (HCC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial.
  2. The goal of phase II trial is to evaluate the safety and efficacy of AK112 in combination therapy or monotherapy in the treatment of HCC compared to the combination of Sintilimab and Bevacizumab biosimilar.
03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able and willing to provide written .
  2. Have a of at least 3 months.
  3. Have an (ECOG) performance status of 0 or 1.
  4. HCC confirmed by histology/cytology or confirmed by the American Society for the Study of Hepatology (AASLD) clinical diagnostic criteria for hepatocellular carcinoma in patients with cirrhosis.
  5. Phase Ib:

    1. Barcelona Clinical Liver Cancer (BCLC) stage B or C.
    2. Has failed standard treatment and has received no more than two lines of anti-tumor treatment in the past;

    Phase II:

    1. The BCLC staging is stage C, which is not suitable for curative and local treatment, or for stage B that cannot be cured after curative and/or local treatment.
    2. Subjects who have not received any systematic anti-tumor treatment for HCC in the past.
  6. According to v1.1, there is at least one untreatable , or a measurable lesion with clear imaging progression after local treatment, suitable for repeated and accurate measurement.
  7. Liver function grading Grade A.
  8. Has adequate organ function.
  9. All subjects of must agree to use an effective method of , as determined by the Investigator, during and for 120 days after the last dose of study treatment.
  10. Able to to comply with all requirements of study participation (including all study procedures).

Exclusion criteria

Exclusion Criteria:

  1. Components confirmed by histology/cytology, such as fibrous layer hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, and cholangiocarcinoma.
  2. Except for HCC, the subjects had other malignant tumors within the 5 years prior to enrollment. Subjects with other malignant tumors that have been cured through local treatment are not excluded, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, cervical or breast cancer in situ. If diagnosed with liver cancer or other malignant tumors more than 5 years before administration, pathological or cytological diagnosis of recurrent and lesions is required.
  3. Tumor volume>50% liver volume; Portal vein cancer thrombus (Vp4), inferior vena cava cancer thrombus.
  4. Tumors invade important organs and blood vessels around them, and researchers have determined that entering the study will cause a higher risk of bleeding.
  5. There is central nervous system (CNS) metastasis, spinal cord compression, or meningeal metastasis.
  6. There are pleural effusion, pericardial effusion, or ascites with clinical symptoms or requiring repeated drainage.
  7. Previously received immunotherapy, including , immune checkpoint agonists, immune cell therapy, and any other treatments targeting the immune mechanisms of tumors.
  8. Received local treatment for the liver within 4 weeks prior to the first administration; Received palliative radiotherapy for non liver patients within 2 weeks prior to initial administration.
  9. There is a history of non infectious pneumonia that requires systemic treatment, or current lung diseases including but not limited to interstitial lung disease, pneumoconiosis, silicosis, drug-related pneumonia, and severely impaired lung function.
  10. History of severe bleeding tendency or coagulation dysfunction.
  11. Previous history of myocarditis, cardiomyopathy, and malignant arrhythmia.
  12. Any arterial or venous thromboembolism events, , cerebrovascular accidents, hypertensive crises, or hypertensive encephalopathy occurred within 6 months prior to the first administration of medication.
  13. Pregnant or lactating female subject.
  14. Any prior or concurrent disease, treatment, or laboratory test abnormality that may confuse study results, affect subjects' full participation in the study, or may not be in their best interest to participate.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    AK112 in combination with AK130

    Drug: AK112 · Drug: AK130

  • Experimental
    AK112 in combination with AK127

    Drug: AK112 · Drug: AK127

  • Experimental
    AK112 in combination with Cadonilimab

    Drug: AK112 · Drug: Cadonilimab

  • Experimental
    AK112

    Drug: AK112

  • Active comparator
    Sintilimab in combination with Bevacizumab biosimilar

    Drug: Sintilimab Injection · Drug: Bevacizumab biosimilar

Interventions

06

What researchers measure

Primary outcomes

  1. Number of subjects with dose limiting toxicities (DLTs)

    DLTs will be assessed during the first three weeks of treatment. DLTs are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the DLT observation period.

    Time frame: During the first three weeks.

  2. Number of subjects with adverse events (AEs)

    AE refers to any untoward medical occurrence or deterioration of existing medical event after the subject signed the ICF, whether or not considered related to the study treatment.

    Time frame: From the time of informed consent signed through 90 days after the last dose of study drug.

  3. Objective Response Rate (ORR) (Phase II)

    ORR is defined as the proportion of subjects with BOR response of CR or PR (based on RECIST Version 1.1).

    Time frame: Up to approximately 2 years.

Secondary outcomes

  1. Objective Response Rate (ORR) (Phase Ib)

    ORR is defined as the proportion of subjects with BOR response of CR or PR (based on RECIST Version 1.1).

    Time frame: Up to approximately 2 years.

  2. Objective Response Rate (ORR) Per mRECIST

    ORR is defined as the proportion of subjects with BOR response of CR or PR (based on mRECIST).

    Time frame: Up to approximately 2 years.

  3. Disease control rate (DCR)

    DCR is defined as the proportion of subjects with response of CR, PR and SD (based on RECIST Version 1.1).

    Time frame: Up to approximately 2 years.

  4. Duration of Response (DoR)

    The time from first documented evidence of CR or PR until time of first documented disease progression.

    Time frame: Up to approximately 2 years.

  5. Progression Free Survival (PFS)

    PFS is defined as the interval between first dose and the earliest date of disease progression or death due to any cause.

    Time frame: Up to approximately 2 years.

  6. Time to response (TTR)

    Time between date of start of treatment until first documented response (CR or PR).

    Time frame: Up to approximately 2 years

  7. Overall survival (OS)

    OS is defined as the time from first dose until death due to any cause

    Time frame: From baseline until death due to any cause.

07

Study locations

2 of 2 sites recruiting
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality, China
    Recruiting
    • Jianqiang Cai · Contact
  • Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital)
    Jinan, Shandong, China
    Recruiting
    • Jinming Yu · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jun 2026, 21 months after the start.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's planned 21 months is below that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2024
First posted
Jul 31, 2024
StartActual
Sep 24, 2024
Primary completionEst.
Jun 2026
CompletionEst.
Sep 2028
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06530251
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Jul 31, 2024
Start date
Sep 24, 2024
Primary completion
Jun 2026 (estimated)
Completion
Sep 2028 (estimated)
Last update
Mar 4, 2026

Study contacts

Wenting Li
Contact
wenting01.li@akesobio.com
18116403289

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivonescimab

Start the discussion